Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Public ClinicalTrials.gov record NCT00031837. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective Randomized Controlled Multicenter Study of the Effect of Dalteparin on Quality of Life in Unresectable Pancreatic Cancer
Study identification
- NCT ID
- NCT00031837
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Gary Morrow
- Other
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Interventions
- dalteparin Drug
- gemcitabine hydrochloride Drug
- quality-of-life assessment Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2002
- Primary completion
- Nov 30, 2006
- Completion
- Nov 30, 2006
- Last update posted
- Oct 13, 2015
2002 – 2006
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MBCCOP - Gulf Coast | Mobile | Alabama | 36607 | — |
| CCOP - Colorado Cancer Research Program, Incorporated | Denver | Colorado | 80224 | — |
| MBCCOP - University of Illinois at Chicago | Chicago | Illinois | 60612-7323 | — |
| CCOP - Central Illinois | Decatur | Illinois | 62526 | — |
| CCOP - Kalamazoo | Kalamazoo | Michigan | 49007-3731 | — |
| CCOP - Kansas City | Kansas City | Missouri | 64131 | — |
| CCOP - Hematology-Oncology Associates of Central New York | East Syracuse | New York | 13057 | — |
| University of Rochester Cancer Center CCOP Research Base | Rochester | New York | 14642 | — |
| CCOP - Southeast Cancer Control Consortium | Goldsboro | North Carolina | 27534-9479 | — |
| CCOP - Columbus | Columbus | Ohio | 43215 | — |
| CCOP - Dayton | Dayton | Ohio | 45429 | — |
| CCOP - Greenville | Greenville | South Carolina | 29615 | — |
| CCOP - Northwest | Tacoma | Washington | 98405-0986 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00031837, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2015 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00031837 live on ClinicalTrials.gov.